TT Epaper
The Telegraph
TT Photogallery
 
IN TODAY'S PAPER
WEEKLY FEATURES
CITIES AND REGIONS
ARCHIVES
Since 1st March, 1999
 
THE TELEGRAPH
 
 
CIMA Gallary
Email This Page
Cadila under US scanner

Mumbai, July 6: Cadila Healthcare Ltd has received a warning letter from the US Food and Drug Administration (USFDA) for violating current good manufacturing practices (CGMP) regulations at its new injectibles facility in Gujarat.

The US health regulator has issued a warning to Cadila Healthcare for the violation of CGMP regulations for finished pharmaceuticals at its facility in Gujarat. It has now given Cadila Healthcare 15 days to notify its office of the specific steps taken by the firm to correct the violations.

According to the US drug regulator, it had identified significant violations of CGMP regulations for finished pharmaceuticals during its inspection of the company’s plant at Sanand in Gujarat.

The USFDA, which inspected the plant between January 17 and February 3, said it had reviewed the firm’s response to its observations on February 10, and noted that it lacked sufficient corrective actions. “Your firm’s laboratory records fail to include complete data derived from all tests necessary to assure compliance with established specifications and standards,” it said. The USFDA cited the example of inability of the company’s microbiologists to identify microbial growth correctly.

Meanwhile, the USFDA has imposed an import ban on products made at Dr Reddy’s Laboratories’ Mexican plant for violation of CGMP regulations.

Top
Email This Page
 
 
" "